Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic...

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Chronic kidney disease (CKD) is linked to high cardiovascular morbidity and mortality, exceeding traditional risk factors.
• Urea in CKD patients can form cyanate, leading to protein carbamylation.
• Carbamylated low-density lipoprotein (cLDL) exhibits pro-atherosclerotic properties.

Purpose of the Study:

• To investigate the role of carbamylated low-density lipoprotein (cLDL) in cardiovascular disease in chronic kidney disease (CKD).
• To assess the association between plasma cLDL levels and cardiovascular events in CKD patients.

Main Methods:

• Analysis of carbamylation process and its effects on proteins, specifically LDL.
• Review of existing human data on cLDL levels in hemodialysis patients.
• Examination of two clinical studies correlating plasma carbamylated protein levels with cardiovascular outcomes.

Main Results:

• Carbamylated low-density lipoprotein (cLDL) promotes endothelial injury, inflammation, and vascular smooth muscle cell proliferation.
• cLDL enhances oxidant generation and activates endonuclease G, contributing to cellular damage.
• Elevated cLDL levels are observed in hemodialysis patients, particularly those with atherosclerosis.
• Plasma carbamylated protein levels independently predicted increased risk of coronary artery disease, myocardial infarction, stroke, and death.

Conclusions:

• Carbamylated low-density lipoprotein (cLDL) is a significant factor in the cardiovascular complications of chronic kidney disease (CKD).
• Elevated cLDL levels serve as an independent predictor of adverse cardiovascular outcomes in CKD patients.
• Further prospective studies are required to confirm the predictive value and establish causality of cLDL in CKD-related cardiovascular disease.